The IFI27 Knockout MCF-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of MCF-7 human breast adenocarcinoma cells with targeted disruption of the IFI27 gene. This knockout model enables loss-of-function studies of IFI27, an interferon-inducible pro-apoptotic protein, in an estrogen receptor-positive breast cancer background. The heterogeneous editing outcomes of the polyclonal pool provide a robust tool for examining IFI27-dependent phenotypes without clonal selection bias. Supplied as a ready-to-use mixed cell population, it integrates easily into standard assay workflows.
The MCF-7 host line is a widely used model of hormone-responsive breast adenocarcinoma. Derived from a metastatic pleural effusion, these cells express estrogen receptor (ER) and progesterone receptor (PR), harbor wild-type p53, and respond to estrogen stimulation. These features make MCF-7 ideal for studying the intersection of hormone signaling and interferon-mediated apoptosis. Established protocols for hormone manipulation further facilitate mechanistic investigations.
IFI27 is a type I interferon-inducible pro-apoptotic protein. Upon IFN-??/?? stimulation, the STAT1-STAT2-IRF9 (ISGF3) complex transcriptionally activates IFI27. The IFI27 protein localizes to mitochondria and binds to anti-apoptotic Bcl-2 family members such as Bcl-2 and Bcl-xL, inhibiting their function. This disrupts mitochondrial membrane integrity, releasing cytochrome c into the cytosol, which activates caspase-9 and caspase-3. Caspase-3 then cleaves downstream substrates like PARP, executing apoptosis. Thus, IFI27 links extracellular interferon signals to the intrinsic apoptotic pathway.
In MCF-7 cells, IFI27 knockout allows dissection of the interplay between interferon signaling, apoptosis, and hormone-responsive pathways. Breast cancer cells often resist apoptosis, and IFI27 loss may contribute to enhanced survival or altered drug sensitivity. This model enables exploration of how IFI27 absence affects type I interferon responses, which have direct anti-tumor and immunomodulatory effects. Moreover, the hormone-responsive nature of MCF-7 permits investigation of potential crosstalk between estrogen signaling and IFI27-regulated apoptosis, relevant to drug resistance in ER-positive breast cancers.
Applications include mechanism-focused studies of interferon-induced apoptosis, definition of IFI27 roles in viral replication inhibition, and exploration of apoptotic defects in breast cancer progression. Assays recommended: Western blotting for IFI27, cleaved caspase-3, and PARP; flow cytometry with Annexin V/propidium iodide for apoptosis; RT-qPCR for IFI27 mRNA; immunofluorescence for mitochondrial localization; and MTT cell viability assays. For further information, please contact Ascent Research.
